The latest furore surrounding the National Health Service reads like a bad novel, but the protagonist is no fiction. Chimamanda Ngozi Adichie, the celebrated Nigerian author, has accused a British hospital trust of deliberately dragging its feet over the death of her son. It is a story that will unsettle anyone who has ever placed a loved one in the care of the state. And if you have any sense, it will make you demand answers about how our institutions handle the ultimate accountability: a child’s death.
Let me parse this with the cold eye of a balance sheet. The NHS is a vast public monopoly. It spends over £190 billion a year. But it operates with a deficit of transparency that would make a private equity firm blush. When a child dies in hospital, the trust’s first instinct is often to circle the wagons. A delay in a death review is not just a bureaucratic hiccup. It is a systematic failure of governance. In financial terms, this is a material weakness in internal controls. The trust’s failure to deliver timely answers is a liability that will compound interest in the court of public opinion.
Adichie’s specific grievance is that the trust has “stalled” the review for months. This is not an isolated incident. It mirrors a pattern we see across the public sector: a reluctance to confront failure. In the City, we call this a “dead cat bounce”: you hope the bad news disappears if you ignore it long enough. But in healthcare, that strategy is lethal. A death review is not a regulatory burden; it is a moral obligation. To delay it is to compound the grief of a mother and to undermine trust in the system itself.
The trust’s response has been predictably opaque. They cite “complexities” and “ongoing investigations.” This is the language of obfuscation. In any efficient market, such opacity would be punished by a sharp decline in the share price. But the NHS has no share price. It has only the suffering of patients and the goodwill of the taxpayer. And that goodwill is a finite resource.
We must ask: what is the cost of this stalling? First, there is the emotional cost, which is incalculable. Then there is the reputational cost for the trust and the NHS as a whole. And finally, there is the opportunity cost: the resources spent on legal manoeuvring could instead be used to improve patient safety. In finance, we talk about “sunk costs.” Here, the sunk cost is trust itself.
Central bank policy metaphor: the Bank of England would never delay a key interest rate decision for months. It would be a disaster for market confidence. Why should a hospital trust be allowed to delay a death review? The answer is that the NHS faces no market discipline. It is a protected monopoly. And monopolies always become sclerotic and unaccountable.
The Adichie case should be a wake-up call. It is not just about one family’s tragedy. It is about a system that has lost its moral compass. The state’s duty to its citizens is not just to provide care. It is to provide accountability when care fails. If the NHS cannot deliver that, then perhaps we need a different model. Perhaps we need more competition. More transparency. More personal responsibility. In short, we need a healthcare system that treats patients like shareholders and trusts like companies that can be sued for malpractice.
Until then, stories like Adichie’s will keep coming. And each one will erode the last remaining asset of the NHS: the public’s faith.
The bottom line: this is not just a hospital scandal. It is a failure of the entire philosophy of centralised, state-run healthcare. The market may be imperfect, but at least it has a mechanism for punishment. In the NHS, the only punishment is a mother’s silence. And thanks to Chimamanda Adichie, that silence is finally broken.
